We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Fatty Acids Profiles Related to Biomarkers in GDM Progression

By LabMedica International staff writers
Posted on 25 Nov 2021
Print article
Image: The Hewlett Packard HP 5890 Series II Plus Gas Chromatograph (GC) System (Photo courtesy of American Laboratory Trading)
Image: The Hewlett Packard HP 5890 Series II Plus Gas Chromatograph (GC) System (Photo courtesy of American Laboratory Trading)
Gestational diabetes mellitus (GDM) is a condition in which a hormone made by the placenta prevents the body from using insulin effectively. Glucose builds up in the blood instead of being absorbed by the cells.

Fatty acids (FAs) are mainly composed of plasma phospholipids, cholesterol esters, triglycerides, and erythrocyte total phospholipids, all of which have been implicated in the pathogenesis of cardiometabolic disorders via their associations with insulin resistance, β-cell dysfunction, inflammation, glucose transporter inhibition, and lipotoxicity.

A team of medical scientists led by those at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (Bethesda, MD, USA) recruited from a large cohort of 2,802 pregnant women, 85 GDM cases using the Carpenter and Coustan criteria and 85 non-GDM controls after exclusion. Upon enrollment at 8 to 13 weeks gestational age (GA) (visit 0), women were scheduled to attend five follow-up visits with blood collection at targeted weeks of GA.

The team examined three subclasses of plasma phospholipid FAs, including plasma phospholipid saturated FA (SFAs), polyunsaturated FA (PUFAs), and monounsaturated FAs (MUFAs) via the Hewlett Packard 5890 gas chromatography system (Palo Alto, CA, USA). The content of individual SFAs, PUFAs, and MUFAs was expressed as weight percentage of the total plasma phospholipid FAs. They assayed all case-control matched samples in a random order in the same analytic run and then performed 40 repeats in each batch among the in-house pooled control samples from the same cohort to assess the interassay CV.

The investigators reported that eight FAs showed significant fold changes from the baseline values (23–31 weeks) among GDM cases as compared to women without GDM. Five FAs showed reduced fold changes: myristic acid (14:0), palmitic acid (16:0), cis-palmitoleic acid (16:1n7), alpha-linolenic acid (18:3n3), and dihomo-gamma-linoleic acid (20:3n6), whereas three showed increases: heptadecanoic acid (17:0), cis-vaccenic acid (18:1n7), and arachidonic acid (20:4n6).

The authors concluded that they had identified eight plasma phospholipid FAs [SFAs: myristic acid (14:0), palmitic acid (16:0), and heptadecanoic acid (17:0); PUFAs: ALA (18:3n3), DGLA (20:3n6), and AA (20:4n6); MUFAs: palmitoleic acid (16:1n7) and vaccenic acid (18:1n7)] with unique patterns of change before and after GDM diagnosis. Such changes of FAs differed significantly between women with and without GDM during the same time window in pregnancy. The study was published on October 11, 2021 in the journal Clinical Chemistry.

Related Links:
National Institute of Child Health and Human Development
Hewlett Packard


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Molecular Diagnostics

view channel
Image: The utilization of liquid biopsies in cancer research is a rapidly developing field (Photo courtesy of Lightspring/Shutterstock)

Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis

B-cell lymphoma is the predominant form of cancer affecting the lymphatic system, with about 30% of patients with aggressive forms of this disease experiencing relapse. Currently, the disease’s risk assessment... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: The Sampler device could revolutionize sample collection for diagnostic tests (Photo courtesy of ReadyGo Diagnostics)

First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests

The COVID pandemic has dramatically reshaped the perception of diagnostics. Post the pandemic, a groundbreaking device that combines sample collection and processing into a single, easy-to-use disposable... Read more